PCSK9 Inhibitors | Zendy

Pradeep Natarajan | Zendy; Sekar Kathiresan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PCSK9 Inhibitors

Author(s) -

Pradeep Natarajan,

Sekar Kathiresan

Publication year - 2016

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2016.05.016

Subject(s) - evolocumab , alirocumab , pcsk9 , proprotein convertase , kexin , ldl receptor , biology , subtilisin , receptor , monoclonal antibody , monoclonal , lipoprotein , cholesterol , medicine , pharmacology , endocrinology , antibody , biochemistry , immunology , enzyme , apolipoprotein a1

Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative agent for atherosclerotic cardiovascular disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research